Literature DB >> 21392921

Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

S F Teunissen1, H Rosing, M Dominguez Seoane, L Brunsveld, J H M Schellens, A H Schinkel, J H Beijnen.   

Abstract

A comprehensive overview is presented of currently known phase I metabolites of tamoxifen consisting of their systematic name and molecular structure. Reference standards are utilized to elucidate the MS(n) fragmentation patterns of these metabolites using a linear ion trap mass spectrometer. UV-absorption spectra are recorded and absorption maxima are defined. Serum extracts from ten breast cancer patients receiving 40mg tamoxifen once daily were qualitatively analyzed for tamoxifen phase I metabolites using a liquid chromatography-tandem mass spectrometry set-up. In total, 19 metabolites have been identified in these serum samples. Additionally a synthetic method for the preparation of the putative metabolite 3',4'-dihydroxytamoxifen is described.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392921     DOI: 10.1016/j.jpba.2011.02.009

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?

Authors:  Ariana E Huber-Wechselberger; Paul Niedetzky; Irene Aigner; Elisabeth Haschke-Becher
Journal:  Wien Med Wochenschr       Date:  2012-06-12

2.  Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Authors:  N G L Jager; H Rosing; S C Linn; J H M Schellens; J H Beijnen
Journal:  Breast Cancer Res Treat       Date:  2012-03-03       Impact factor: 4.872

3.  Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.

Authors:  Ewa E Hennig; Magdalena Piatkowska; Jakub Karczmarski; Krzysztof Goryca; Elzbieta Brewczynska; Radoslaw Jazwiec; Anna Kluska; Robert Omiotek; Agnieszka Paziewska; Michal Dadlez; Jerzy Ostrowski
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

4.  Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

Authors:  Nynke G L Jager; Rutger H T Koornstra; Andrew D Vincent; Ron H N van Schaik; Alwin D R Huitema; Tiny M Korse; Jan H M Schellens; Sabine C Linn; Jos H Beijnen
Journal:  BMC Cancer       Date:  2013-12-28       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.